Loading...
•
Sep 27, 2020
Illumina Q3 2020 Earnings Report
Reported strong sequential growth driven by sequencing consumable revenue and progress in incorporating genomics into standard of care.
Key Takeaways
Illumina's third quarter 2020 results showed strong sequential growth with revenue of $794 million, a 26% increase compared to the second quarter of 2020, although a 12% decrease compared to the prior year period. GAAP net income was $179 million, or $1.21 per diluted share, while non-GAAP net income was $150 million, or $1.02 per diluted share.
Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period
GAAP net income attributable to Illumina stockholders for the quarter of $179 million, or $1.21 per diluted share
Non-GAAP net income attributable to Illumina stockholders for the quarter of $150 million, or $1.02 per diluted share
Free cash flow of $105 million for the quarter compared to $218 million in the prior year period
Forward Guidance
Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the uncertainties around the severity and duration of the COVID-19 pandemic.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...